Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.

Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R, Zhao J. · 2018

Read Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. by Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R, Zhao J. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6146601.txt.

Description

Shen and co-authors wrote a review in Journal of Hematology and Oncology on anlotinib, a new cancer drug taken by mouth. Anlotinib blocks several tyrosine kinases, enzymes that help tumors grow and build blood vessels. Its targets include receptors for VEGF, FGF, and PDGF, plus c-kit.

The review sums up the drug's clinical development. In a phase III trial, it beat placebo on survival in advanced lung cancer that had progressed after two prior treatments. China's drug agency approved it as a third-line option for that cancer. A further trial showed longer time without growth in soft tissue sarcoma. Readers get one account of where this multi-target drug stands.

Catalog record

CREATORShen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R, Zhao J.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6146601

Browse the full library · About the Tower of Babel